Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study (ILIT-FNA)
Hypersensitivity, Hay Fever, Rhinitis, Allergic, Seasonal
About this trial
This is an interventional basic science trial for Hypersensitivity
Eligibility Criteria
Inclusion Criteria: Patients who have seasonal grass-pollen-induced rhinoconjunctivitis as confirmed by patient history and type-1-sensitization to grass-pollen in skin and/or serum. Patients that undergo pre-seasonal short-term scheme with Polvac™ SCIT at the USZ Allergy Unit in autumn and winter 2023 for treatment of allergic rhinoconjunctivitis. Informed Consent as documented by signature. Patients are between 18 and 55 years of age when they sign the informed consent. Exclusion Criteria: Known or suspected allergy to additives to the study product Known intolerance or allergy to phenol Planned depot steroid injection for treatment of allergic rhinoconjunctivitis Uncontrolled asthma or severe asthma with post bronchodilator FEV1<70%, decided by the investigator Pulmonary disease with post bronchodilator FEV1 < 70 % of predicted Pulmonary disease, perennial or seasonal, with daily use of more than 800 microgram inhaled budesonide/day (or equivalent) Treatment with omalizumab or other biologics for allergy, AD, urticaria or asthma. Allergic reaction within the last 4 days or anaphylaxis within last month before planned ILIT or SCIT injection.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Subcutaneous immunotherapy
Intralymphatic immunotherapy
Subcutaneous injection of grass-rye pollen allergen extract and micro-crystalline tyrosine. Single dose of 2000 U allergen in 0.5 ml. Dosage form: aqueous suspension.
Subcutaneous injection of grass-rye pollen allergen extract and micro-crystalline tyrosine. Single dose of 400 U allergen in 0.1 ml. Dosage form: aqueous suspension.